Profiles

Keywords
Last Name
Institution

John Somberg

Concepts (588)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Anti-Arrhythmia Agents
55
2016
89
8.760
Why?
Drug Approval
19
2013
34
6.640
Why?
United States Food and Drug Administration
36
2014
70
6.520
Why?
Drug Industry
21
2013
28
5.070
Why?
Electrocardiography
49
2015
198
4.640
Why?
Clinical Trials as Topic
26
2014
366
4.540
Why?
United States
72
2014
1991
4.390
Why?
Amiodarone
18
2016
28
4.210
Why?
Pharmaceutical Preparations
10
2012
18
4.140
Why?
Arrhythmias, Cardiac
36
2010
128
4.100
Why?
Humans
213
2018
25732
3.880
Why?
Device Approval
8
2014
16
3.860
Why?
Drug-Related Side Effects and Adverse Reactions
12
2018
32
3.590
Why?
Heart Failure
14
2015
177
3.130
Why?
Drug Design
6
2014
36
3.030
Why?
Tachycardia
33
2013
43
2.900
Why?
Equipment Design
8
2014
177
2.770
Why?
Research
12
2014
61
2.710
Why?
Equipment and Supplies
5
2011
14
2.630
Why?
Diuretics
6
2009
13
2.570
Why?
Drug Prescriptions
8
2008
23
2.550
Why?
Hypertension
8
2015
212
2.470
Why?
Atrial Fibrillation
9
2016
120
2.250
Why?
Long QT Syndrome
7
2011
13
2.220
Why?
Ether-A-Go-Go Potassium Channels
5
2008
8
2.080
Why?
Caffeine
3
2015
61
2.070
Why?
Cardiovascular Agents
6
2015
24
2.060
Why?
Sotalol
7
2016
7
1.990
Why?
Periodicals as Topic
5
2015
35
1.990
Why?
Endpoint Determination
4
2014
28
1.850
Why?
Patents as Topic
4
2014
5
1.790
Why?
Blood Pressure
18
2015
208
1.750
Why?
Cardiovascular Diseases
7
2014
300
1.710
Why?
Publishing
4
2015
34
1.630
Why?
Drug Labeling
4
2010
6
1.560
Why?
Politics
5
2010
18
1.560
Why?
Research Support as Topic
5
2013
21
1.550
Why?
Legislation, Drug
5
2008
5
1.530
Why?
Myocardial Infarction
10
2009
167
1.470
Why?
Drug Costs
5
2015
16
1.450
Why?
Biomedical Research
4
2013
78
1.420
Why?
Delivery of Health Care
3
2015
69
1.400
Why?
Advisory Committees
3
2013
35
1.370
Why?
Central Nervous System Stimulants
2
2015
55
1.370
Why?
Analgesics
2
2015
84
1.330
Why?
Chronic Pain
2
2015
72
1.320
Why?
Product Surveillance, Postmarketing
7
2010
17
1.310
Why?
Drug Therapy
5
2012
15
1.260
Why?
Piperidines
17
1987
33
1.240
Why?
Financing, Government
4
2013
14
1.230
Why?
Heart Rate
17
2015
140
1.230
Why?
Disease Outbreaks
3
2014
88
1.190
Why?
Risk Assessment
6
2014
674
1.170
Why?
Conflict of Interest
3
2013
18
1.130
Why?
Vasodilator Agents
5
2009
28
1.130
Why?
Infusions, Intravenous
10
2011
99
1.090
Why?
Female
69
2015
15291
1.070
Why?
Male
73
2015
14935
1.050
Why?
Angiotensin-Converting Enzyme Inhibitors
5
2002
28
1.020
Why?
Hypotension
4
2005
30
1.020
Why?
Health Care Reform
2
2011
17
0.990
Why?
Health Policy
3
2014
41
0.970
Why?
Benzeneacetamides
11
1986
12
0.960
Why?
Quinidine
12
2007
14
0.950
Why?
Genetic Testing
3
2012
72
0.950
Why?
Evidence-Based Medicine
4
2009
207
0.950
Why?
Animals
27
2009
4797
0.940
Why?
Randomized Controlled Trials as Topic
3
2014
300
0.930
Why?
Ethacrynic Acid
2
2009
3
0.930
Why?
Edema
2
2009
35
0.900
Why?
Lidocaine
12
2004
41
0.900
Why?
Oocytes
6
2008
14
0.900
Why?
Internet
2
2015
83
0.870
Why?
Electrophysiology
18
2007
146
0.850
Why?
Sex Characteristics
3
2015
88
0.840
Why?
Drug Combinations
2
2015
85
0.820
Why?
Stroke
2
2011
306
0.810
Why?
Potassium Channels, Voltage-Gated
3
2006
12
0.800
Why?
Dose-Response Relationship, Drug
14
2010
509
0.800
Why?
Time Factors
19
2012
1680
0.800
Why?
Procainamide
19
1987
20
0.790
Why?
Education, Medical, Continuing
2
2008
43
0.780
Why?
Drug Interactions
6
2010
68
0.780
Why?
Digoxin
3
2014
6
0.770
Why?
Platelet Aggregation Inhibitors
4
2010
58
0.770
Why?
Hypoglycemic Agents
2
2010
64
0.750
Why?
Diffusion of Innovation
2
2008
35
0.740
Why?
Hemodynamics
11
2004
100
0.740
Why?
Aminobutyrates
1
2015
1
0.740
Why?
Tetrazoles
1
2015
6
0.730
Why?
Energy Drinks
1
2015
1
0.730
Why?
Syncope, Vasovagal
2
2009
2
0.730
Why?
Coffee
1
2015
3
0.730
Why?
Drug Utilization
3
2006
22
0.730
Why?
Manometry
1
2015
27
0.730
Why?
Thyroid Gland
1
2016
55
0.720
Why?
Nicotine
1
2015
8
0.720
Why?
Global Health
2
2014
51
0.720
Why?
Research Design
3
2007
183
0.720
Why?
Diabetic Neuropathies
1
2015
14
0.710
Why?
Kidney
2
2015
179
0.710
Why?
Myocardial Ischemia
3
2009
52
0.710
Why?
Flecainide
9
2008
12
0.700
Why?
Denervation
1
2015
20
0.700
Why?
Computers
1
2015
19
0.700
Why?
Endothelium, Vascular
1
2015
70
0.690
Why?
Death, Sudden, Cardiac
3
2000
23
0.690
Why?
Middle Aged
52
2010
9627
0.690
Why?
Hemorrhagic Fever, Ebola
1
2014
8
0.690
Why?
Sports
2
2008
19
0.680
Why?
Biological Products
2
2007
28
0.670
Why?
Adult
29
2015
8409
0.670
Why?
Defibrillators, Implantable
2
2013
19
0.670
Why?
Public Health
1
2014
46
0.670
Why?
Medical Device Recalls
1
2014
3
0.660
Why?
Practice Guidelines as Topic
2
2012
334
0.660
Why?
Angioplasty, Balloon, Coronary
2
2009
55
0.650
Why?
Heart Valve Prosthesis
1
2014
31
0.650
Why?
Antibodies, Monoclonal
2
2007
302
0.650
Why?
Patient Care
1
2014
30
0.640
Why?
Pain Management
1
2015
110
0.640
Why?
Sulfonamides
4
2016
56
0.640
Why?
Communication
1
2015
91
0.640
Why?
Supreme Court Decisions
1
2013
1
0.630
Why?
Equipment Safety
2
2010
13
0.630
Why?
Quality Assurance, Health Care
1
2014
52
0.630
Why?
Federal Government
1
2013
4
0.620
Why?
Patient Protection and Affordable Care Act
1
2013
17
0.620
Why?
Genes, BRCA1
1
2013
12
0.620
Why?
Piperazines
3
2009
83
0.620
Why?
Genes, BRCA2
1
2013
12
0.620
Why?
Guidelines as Topic
1
2014
73
0.620
Why?
Electrocardiography, Ambulatory
3
2015
20
0.610
Why?
Torsades de Pointes
3
2011
11
0.610
Why?
Tachycardia, Ventricular
2
2004
24
0.610
Why?
Comparative Effectiveness Research
1
2013
7
0.610
Why?
Cardiac Pacing, Artificial
16
1987
47
0.610
Why?
Xenopus laevis
6
2008
10
0.600
Why?
Registries
2
2004
150
0.600
Why?
Action Potentials
4
2006
112
0.590
Why?
Metagenome
1
2012
20
0.580
Why?
Diabetes Mellitus
2
2011
100
0.580
Why?
Drug and Narcotic Control
2
2010
8
0.580
Why?
Bioterrorism
2
2002
6
0.570
Why?
Antithrombins
1
2011
6
0.560
Why?
Drugs, Generic
2
2002
4
0.550
Why?
Drug Delivery Systems
2
2015
38
0.550
Why?
Therapies, Investigational
1
2011
4
0.550
Why?
Risk Factors
9
2016
2208
0.540
Why?
Cross Infection
1
2014
262
0.540
Why?
Hypotension, Orthostatic
2
2010
16
0.540
Why?
Pediatrics
2
2003
50
0.540
Why?
Anticholesteremic Agents
2
2008
21
0.530
Why?
Drug Discovery
1
2011
26
0.530
Why?
Heart Conduction System
7
2002
26
0.530
Why?
Cyclooxygenase Inhibitors
3
2006
40
0.520
Why?
Product Recalls and Withdrawals
1
2010
1
0.520
Why?
Fibrinolytic Agents
1
2011
85
0.520
Why?
Sympathomimetics
1
2010
5
0.520
Why?
Midodrine
1
2010
2
0.520
Why?
Administration, Oral
12
2016
150
0.520
Why?
Adrenergic beta-Antagonists
7
2016
39
0.510
Why?
Drug Evaluation
10
2002
57
0.510
Why?
Antihypertensive Agents
3
2014
62
0.510
Why?
Angina Pectoris
2
2004
18
0.510
Why?
Aged
39
2010
8523
0.510
Why?
Potassium
2
2007
66
0.510
Why?
Hospitalization
2
2014
262
0.500
Why?
Chemistry, Pharmaceutical
4
2005
14
0.500
Why?
Cytochrome P-450 Enzyme System
1
2010
10
0.500
Why?
Global Warming
1
2010
1
0.500
Why?
Decision Making
1
2012
175
0.490
Why?
Anticoagulants
1
2011
122
0.490
Why?
Therapeutic Equivalency
5
2016
8
0.490
Why?
Dementia, Vascular
1
2010
39
0.490
Why?
Muscle Contraction
2
2007
83
0.480
Why?
Technetium
1
2009
6
0.480
Why?
Cost Control
1
2009
11
0.480
Why?
Thiophenes
1
2009
14
0.480
Why?
Heart Ventricles
18
2008
188
0.470
Why?
Technology, Pharmaceutical
1
2009
2
0.470
Why?
Ventricular Function
2
2008
14
0.470
Why?
Radiopharmaceuticals
1
2009
55
0.470
Why?
Neurology
1
2011
98
0.460
Why?
Insulin
1
2010
90
0.460
Why?
Ascites
1
2009
5
0.460
Why?
Medication Errors
2
2000
19
0.460
Why?
Genetics
2
2006
2
0.460
Why?
Natriuretic Peptide, Brain
2
2006
10
0.460
Why?
Methadone
1
2008
7
0.460
Why?
Patient Selection
2
2007
227
0.460
Why?
Licensure, Medical
1
2008
2
0.450
Why?
Catheter Ablation
1
2009
44
0.450
Why?
Catheterization
1
2009
61
0.450
Why?
Drug-Eluting Stents
1
2008
11
0.450
Why?
Acidosis
2
2005
4
0.450
Why?
Rats
7
2007
939
0.440
Why?
Authorship
1
2008
14
0.440
Why?
Clinical Trials, Phase I as Topic
1
2008
9
0.440
Why?
Substance Abuse Detection
1
2008
5
0.440
Why?
Street Drugs
1
2008
9
0.440
Why?
Self Disclosure
1
2008
12
0.440
Why?
Fees and Charges
1
2008
8
0.430
Why?
Enzyme Inhibitors
1
2009
151
0.430
Why?
Doping in Sports
1
2008
2
0.430
Why?
Signal Processing, Computer-Assisted
1
2008
44
0.430
Why?
Hypercholesterolemia
1
2008
29
0.430
Why?
Food-Drug Interactions
1
2007
1
0.430
Why?
Flavanones
1
2007
3
0.430
Why?
Hypolipidemic Agents
2
2014
27
0.420
Why?
Beverages
1
2007
14
0.420
Why?
Heart Diseases
2
2008
88
0.420
Why?
Government Regulation
3
2015
7
0.420
Why?
Ethics Consultation
1
2007
1
0.410
Why?
Analgesics, Opioid
1
2008
114
0.410
Why?
Heart Septal Defects, Atrial
1
2007
23
0.410
Why?
Metolazone
1
2007
1
0.400
Why?
Diuresis
1
2007
2
0.400
Why?
Physician's Role
1
2007
19
0.400
Why?
Furosemide
1
2007
2
0.400
Why?
Graft Occlusion, Vascular
1
2007
21
0.400
Why?
Myocardial Contraction
5
2005
77
0.400
Why?
Databases as Topic
1
2006
20
0.390
Why?
Social Control, Formal
3
2001
3
0.390
Why?
Patch-Clamp Techniques
4
2007
135
0.390
Why?
Retrospective Studies
6
2015
2588
0.390
Why?
Pharmacology, Clinical
2
2004
3
0.390
Why?
Gastrointestinal Tract
1
2007
52
0.390
Why?
Electrodes
1
2006
17
0.380
Why?
Information Dissemination
2
2004
19
0.380
Why?
In Vitro Techniques
4
2007
253
0.380
Why?
Electric Stimulation
12
2004
90
0.380
Why?
Security Measures
2
2003
4
0.380
Why?
Erythromycin
1
2006
16
0.370
Why?
Verapamil
7
2009
34
0.370
Why?
Natriuretic Agents
1
2005
1
0.370
Why?
Hyperkalemia
2
2006
5
0.370
Why?
Hypnotics and Sedatives
1
2006
24
0.370
Why?
Pyridines
1
2006
44
0.370
Why?
Administration, Topical
2
2015
21
0.360
Why?
Water
2
2003
36
0.360
Why?
Hypokalemia
2
2005
7
0.360
Why?
Healthy Volunteers
2
2015
36
0.360
Why?
Prostheses and Implants
1
2007
160
0.360
Why?
Magnesium Sulfate
1
2005
9
0.360
Why?
Human Experimentation
2
2002
2
0.350
Why?
Young Adult
4
2015
1802
0.350
Why?
Antineoplastic Agents
2
2009
292
0.350
Why?
Stents
1
2007
149
0.350
Why?
Coronary Disease
4
1998
98
0.340
Why?
Ethics, Medical
2
2001
17
0.340
Why?
Anti-Obesity Agents
1
2004
6
0.330
Why?
Liability, Legal
3
2012
6
0.330
Why?
Rats, Sprague-Dawley
4
2007
489
0.330
Why?
Heart Arrest
4
1997
44
0.330
Why?
Nonprescription Drugs
1
2004
2
0.330
Why?
Prescription Fees
1
2003
1
0.320
Why?
Imidazoles
6
1987
65
0.320
Why?
Stereoisomerism
4
2008
22
0.320
Why?
Sensitivity and Specificity
4
2008
575
0.320
Why?
Publication Bias
1
2003
6
0.320
Why?
Adverse Drug Reaction Reporting Systems
2
2000
8
0.310
Why?
Communicable Diseases, Emerging
1
2003
2
0.310
Why?
Severe Acute Respiratory Syndrome
1
2003
5
0.310
Why?
Teaching
1
2004
62
0.310
Why?
Electric Countershock
5
2013
20
0.310
Why?
Drug Administration Schedule
6
2010
250
0.310
Why?
Clinical Protocols
2
2003
58
0.310
Why?
Blood Pressure Monitoring, Ambulatory
1
2003
4
0.310
Why?
Glyburide
1
2002
1
0.300
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2004
61
0.300
Why?
Metformin
1
2002
10
0.300
Why?
Clinical Competence
1
2005
237
0.300
Why?
Drug Therapy, Combination
4
2009
250
0.300
Why?
Anti-Bacterial Agents
2
2006
371
0.290
Why?
Polymorphism, Genetic
2
2002
90
0.290
Why?
Facility Regulation and Control
1
2002
2
0.290
Why?
1-Octanol
1
2002
1
0.290
Why?
Solvents
1
2002
5
0.290
Why?
Heart Valve Diseases
1
2002
15
0.280
Why?
Public Health Administration
1
2001
9
0.280
Why?
Disaster Planning
1
2001
8
0.280
Why?
Magnesium Compounds
1
2001
2
0.280
Why?
Emergency Medical Services
1
2001
35
0.270
Why?
Accreditation
1
2001
13
0.270
Why?
Calcium Metabolism Disorders
1
2001
1
0.270
Why?
Orphan Drug Production
1
2001
3
0.270
Why?
Ventricular Dysfunction
1
2001
3
0.270
Why?
Stem Cells
1
2001
48
0.270
Why?
Addison Disease
1
2000
1
0.260
Why?
Government Programs
1
2000
2
0.260
Why?
Obesity
1
2004
275
0.260
Why?
Cross-Over Studies
2
2010
68
0.250
Why?
Genetic Markers
3
2012
49
0.250
Why?
Diabetes Mellitus, Type 2
1
2002
181
0.240
Why?
Information Services
1
1999
5
0.240
Why?
Science
1
1999
5
0.240
Why?
Half-Life
4
2009
16
0.240
Why?
Potassium Channels
3
2006
42
0.240
Why?
Pharmacokinetics
2
2002
6
0.230
Why?
Circadian Rhythm
2
2006
262
0.230
Why?
Drug Hypersensitivity
1
1998
15
0.220
Why?
Biological Availability
3
2009
24
0.220
Why?
Dogs
5
2004
273
0.220
Why?
Delayed Rectifier Potassium Channels
2
2007
5
0.220
Why?
Area Under Curve
2
2010
70
0.220
Why?
Alprostadil
1
1997
11
0.210
Why?
Peripheral Vascular Diseases
1
1997
11
0.210
Why?
Arterial Occlusive Diseases
1
1997
17
0.210
Why?
Aged, 80 and over
6
2004
4342
0.210
Why?
Death, Sudden
4
2004
15
0.210
Why?
Heart
5
1992
97
0.200
Why?
Hypertrophy, Left Ventricular
1
1997
28
0.200
Why?
Nitroglycerin
2
1995
4
0.200
Why?
Universities
2
2010
20
0.190
Why?
Risk
4
2011
205
0.190
Why?
Hydrogen-Ion Concentration
2
2007
182
0.190
Why?
Controlled Clinical Trials as Topic
2
2008
6
0.190
Why?
Hydantoins
2
2006
2
0.190
Why?
Imidazolidines
2
2006
2
0.190
Why?
Phenethylamines
2
2006
5
0.190
Why?
Biotechnology
1
2015
3
0.190
Why?
Hypercalcemia
3
2001
8
0.190
Why?
Adolescent
2
2015
2305
0.190
Why?
Treatment Outcome
4
2008
3215
0.190
Why?
Reproducibility of Results
3
2006
751
0.180
Why?
Injections, Intravenous
7
2016
60
0.180
Why?
Diclofenac
1
2015
4
0.180
Why?
Membrane Potentials
2
2007
216
0.180
Why?
Stimulation, Chemical
1
2015
14
0.180
Why?
Ointments
1
2015
3
0.180
Why?
Hypothyroidism
1
2016
64
0.180
Why?
Myocardium
4
2008
173
0.180
Why?
Antibodies, Monoclonal, Humanized
2
2007
108
0.170
Why?
Africa South of the Sahara
1
2014
1
0.170
Why?
Anilides
4
1987
9
0.170
Why?
Journalism, Medical
2
2008
5
0.170
Why?
Sex Factors
2
2008
440
0.170
Why?
Ventricular Fibrillation
5
2006
23
0.170
Why?
Breast Neoplasms
2
2013
393
0.170
Why?
Europe
2
2005
70
0.170
Why?
Phenothiazines
4
1987
4
0.170
Why?
Early Termination of Clinical Trials
1
2014
2
0.170
Why?
Referral and Consultation
1
2015
84
0.160
Why?
Structure-Activity Relationship
2
2005
54
0.160
Why?
Safety
1
2014
54
0.160
Why?
Lobbying
1
2013
1
0.160
Why?
Health Insurance Exchanges
1
2013
1
0.160
Why?
Ouabain
4
1983
6
0.160
Why?
Electricity
1
2013
10
0.150
Why?
Organizational Innovation
2
2003
19
0.150
Why?
Isradipine
1
1993
3
0.150
Why?
Pyrrolidines
4
1985
15
0.150
Why?
Bradycardia
2
2005
22
0.150
Why?
Solubility
2
2003
38
0.150
Why?
Investigational New Drug Application
1
1992
1
0.150
Why?
Pain Measurement
1
2015
406
0.150
Why?
Monitoring, Physiologic
4
2008
86
0.150
Why?
International Cooperation
2
2005
36
0.150
Why?
Electric Stimulation Therapy
1
2013
43
0.150
Why?
Competitive Behavior
1
2012
6
0.150
Why?
Cardiomyopathies
1
2013
31
0.150
Why?
Economics, Pharmaceutical
2
2003
6
0.150
Why?
Unnecessary Procedures
1
2013
26
0.150
Why?
Thallium Radioisotopes
1
1992
4
0.150
Why?
Dipyridamole
1
1992
4
0.150
Why?
Patient Safety
1
2013
43
0.150
Why?
Double-Blind Method
5
2002
502
0.140
Why?
Chemoprevention
1
2011
6
0.140
Why?
Vitamin K
1
2011
6
0.140
Why?
Factor Xa Inhibitors
1
2011
5
0.140
Why?
Prosthesis Design
1
2014
420
0.140
Why?
Safety-Based Medical Device Withdrawals
1
2011
1
0.130
Why?
Disease Models, Animal
2
2006
716
0.130
Why?
Comorbidity
2
2011
474
0.130
Why?
Molecular Biology
1
2011
14
0.130
Why?
Equipment Failure
1
2011
48
0.130
Why?
Paternalism
1
2010
1
0.130
Why?
Public Policy
2
2001
5
0.130
Why?
Cell- and Tissue-Based Therapy
1
2011
14
0.130
Why?
Florida
1
2010
17
0.130
Why?
Bethanidine
3
1985
3
0.130
Why?
Coronary Artery Disease
2
2004
128
0.130
Why?
Acute Disease
2
2009
256
0.130
Why?
Medicaid
1
2011
36
0.130
Why?
Ticlopidine
1
2010
15
0.130
Why?
Medicare
1
2011
72
0.130
Why?
Industry
1
2010
9
0.130
Why?
Quality of Health Care
1
2012
119
0.120
Why?
Exercise Test
5
1995
100
0.120
Why?
Publications
1
2010
8
0.120
Why?
Health Care Costs
1
2011
70
0.120
Why?
Radioisotopes
1
2009
15
0.120
Why?
Lithium Carbonate
2
2000
4
0.120
Why?
Canada
1
2009
45
0.120
Why?
Antimanic Agents
2
2000
12
0.120
Why?
Linear Models
1
2010
257
0.120
Why?
Hepatorenal Syndrome
1
2009
1
0.120
Why?
Glaucoma
1
2009
5
0.120
Why?
Ultrafiltration
1
2009
6
0.120
Why?
Vasoconstrictor Agents
1
2009
27
0.120
Why?
Glutathione Transferase
1
2009
8
0.120
Why?
Hepatic Encephalopathy
1
2009
6
0.120
Why?
Radiation-Sensitizing Agents
1
2009
13
0.110
Why?
Pacemaker, Artificial
1
2009
22
0.110
Why?
Liver Failure
1
2009
13
0.110
Why?
Computer Simulation
1
2010
216
0.110
Why?
National Institutes of Health (U.S.)
1
2009
28
0.110
Why?
Renal Insufficiency
1
2009
18
0.110
Why?
Protein Isoforms
1
2008
52
0.110
Why?
Bipolar Disorder
2
2000
112
0.110
Why?
Cotinine
1
2008
5
0.110
Why?
Azetidines
1
2008
4
0.110
Why?
Drug Resistance, Neoplasm
1
2009
60
0.110
Why?
Research Subjects
1
2008
9
0.110
Why?
Commerce
1
2008
9
0.110
Why?
Prognosis
2
2009
845
0.110
Why?
Simvastatin
1
2008
15
0.110
Why?
Quality Control
1
2008
46
0.110
Why?
Citrus paradisi
1
2007
1
0.110
Why?
Xenopus
1
2007
6
0.110
Why?
Mental Processes
1
2008
17
0.110
Why?
Maximum Tolerated Dose
1
2007
20
0.110
Why?
Anti-Inflammatory Agents
1
2009
97
0.110
Why?
Legislation, Medical
1
2007
1
0.100
Why?
Patient Readmission
1
2009
90
0.100
Why?
Motivation
1
2008
90
0.100
Why?
Child
2
2003
1335
0.100
Why?
Natriuresis
1
2007
3
0.100
Why?
Injections, Intraperitoneal
1
2007
13
0.100
Why?
Quinolines
1
2007
15
0.100
Why?
Cyclooxygenase 2 Inhibitors
1
2007
31
0.100
Why?
Access to Information
1
2006
5
0.100
Why?
Confidentiality
1
2006
9
0.100
Why?
Prospective Studies
2
2004
1520
0.100
Why?
Substance-Related Disorders
1
2008
102
0.100
Why?
Smoking
1
2008
167
0.100
Why?
Coated Materials, Biocompatible
1
2007
43
0.100
Why?
Predictive Value of Tests
1
2009
552
0.100
Why?
Blood Vessel Prosthesis Implantation
1
2007
41
0.100
Why?
Databases, Factual
1
2008
264
0.100
Why?
Probability
1
2006
94
0.100
Why?
Ethanol
1
2008
120
0.100
Why?
Extracellular Matrix
1
2006
90
0.090
Why?
Enterococcus faecalis
1
2006
8
0.090
Why?
Muscle, Smooth
1
2006
15
0.090
Why?
Benzofurans
1
1986
4
0.090
Why?
Acecainide
1
1985
1
0.090
Why?
Tocainide
4
1986
4
0.090
Why?
Microbial Sensitivity Tests
1
2006
110
0.090
Why?
Antidepressive Agents
2
2004
93
0.090
Why?
Extracellular Fluid
1
2005
3
0.090
Why?
Gene Expression Profiling
1
2006
152
0.090
Why?
Aspirin
1
2006
65
0.090
Why?
Feasibility Studies
1
2006
208
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2006
92
0.090
Why?
Incidence
1
2008
692
0.090
Why?
Lethal Dose 50
1
2005
2
0.090
Why?
Trans-Activators
1
2005
30
0.090
Why?
Bepridil
4
1985
4
0.090
Why?
Stroke Volume
3
1999
51
0.090
Why?
Influenza Vaccines
1
2004
9
0.090
Why?
Lactones
1
2004
14
0.090
Why?
Sulfones
1
2004
25
0.090
Why?
Guanidines
1
1984
2
0.090
Why?
National Library of Medicine (U.S.)
1
2004
1
0.090
Why?
Recombinant Proteins
1
2005
291
0.080
Why?
Follow-Up Studies
4
2002
1775
0.080
Why?
Colon
1
2006
132
0.080
Why?
Pharmaceutical Solutions
1
2004
3
0.080
Why?
Aconitine
1
2004
1
0.080
Why?
Self Medication
1
2004
3
0.080
Why?
Sleep Initiation and Maintenance Disorders
1
2006
90
0.080
Why?
Cells, Cultured
1
2006
760
0.080
Why?
Purkinje Fibers
1
1983
2
0.080
Why?
Delayed-Action Preparations
1
2003
36
0.080
Why?
Education, Medical, Undergraduate
1
2004
30
0.080
Why?
Disease Susceptibility
1
2004
67
0.080
Why?
Oligonucleotide Array Sequence Analysis
1
2004
76
0.080
Why?
SARS Virus
1
2003
4
0.080
Why?
Communicable Disease Control
1
2003
9
0.080
Why?
World Health Organization
1
2003
18
0.080
Why?
Algorithms
1
2006
380
0.080
Why?
Travel
1
2003
14
0.080
Why?
Spinal Cord
3
1980
100
0.080
Why?
Australia
1
2003
38
0.080
Why?
Encainide
4
1987
7
0.080
Why?
Centers for Disease Control and Prevention (U.S.)
1
2002
21
0.080
Why?
Moricizine
4
1987
6
0.070
Why?
Baltimore
1
2002
15
0.070
Why?
Ethics Committees, Research
1
2002
4
0.070
Why?
Ventricular Function, Left
1
2002
54
0.070
Why?
Biological Warfare
1
2002
3
0.070
Why?
Indicators and Reagents
1
2002
20
0.070
Why?
Treatment Failure
1
2002
158
0.070
Why?
Chronic Disease
2
1999
465
0.070
Why?
Chromatography, High Pressure Liquid
1
2002
43
0.070
Why?
Civil Defense
1
2002
8
0.070
Why?
Cardiac Complexes, Premature
3
1986
3
0.070
Why?
Digitalis Glycosides
2
2001
3
0.070
Why?
Ethics Committees
1
2001
2
0.070
Why?
Professional Staff Committees
1
2001
9
0.070
Why?
Age Factors
1
2004
794
0.070
Why?
Awareness
1
2001
41
0.070
Why?
Cost-Benefit Analysis
1
2002
122
0.070
Why?
Disopyramide
3
1986
3
0.070
Why?
Hypocalcemia
1
2001
4
0.070
Why?
Informed Consent
1
2001
25
0.070
Why?
Intestinal Absorption
1
2001
44
0.070
Why?
Cognition Disorders
1
2010
1042
0.070
Why?
Tilt-Table Test
1
2000
1
0.070
Why?
Histamine Antagonists
1
1980
2
0.060
Why?
Academic Medical Centers
1
2001
133
0.060
Why?
Decision Making, Computer-Assisted
1
2000
6
0.060
Why?
Propranolol
2
1979
13
0.060
Why?
Aging
1
2010
1265
0.060
Why?
Analysis of Variance
1
2001
361
0.060
Why?
Prevalence
1
2002
477
0.060
Why?
Abstracting and Indexing as Topic
1
1999
3
0.060
Why?
Information Storage and Retrieval
1
1999
5
0.060
Why?
Recurrence
3
1991
332
0.060
Why?
Morbidity
1
1999
57
0.060
Why?
Single-Blind Method
1
1999
121
0.060
Why?
Forecasting
1
1999
117
0.060
Why?
Drug Therapy, Computer-Assisted
1
1998
6
0.060
Why?
Needs Assessment
1
1998
49
0.050
Why?
Resuscitation
1
1997
13
0.050
Why?
Diagnosis, Computer-Assisted
1
1997
18
0.050
Why?
Atrial Flutter
2
1986
13
0.050
Why?
Isosorbide Dinitrate
1
1996
1
0.050
Why?
Echocardiography
1
1997
173
0.050
Why?
Phenytoin
2
1986
11
0.050
Why?
Administration, Sublingual
1
1995
1
0.050
Why?
Ventricular Dysfunction, Left
1
1996
50
0.050
Why?
Data Interpretation, Statistical
1
1995
94
0.040
Why?
Mutation
1
1997
412
0.040
Why?
Infusions, Parenteral
2
1985
14
0.040
Why?
Ajmaline
2
1985
2
0.040
Why?
Aprindine
2
1985
2
0.040
Why?
Bretylium Tosylate
2
1985
2
0.040
Why?
Mexiletine
2
1985
2
0.040
Why?
Propiophenones
2
1985
3
0.040
Why?
Propafenone
2
1985
3
0.040
Why?
Severity of Illness Index
1
1999
1115
0.040
Why?
Cost Sharing
1
1992
2
0.040
Why?
Suspensions
1
1992
4
0.040
Why?
Tablets
1
1992
6
0.040
Why?
Radionuclide Imaging
1
1992
62
0.040
Why?
Metabolic Clearance Rate
1
1991
8
0.040
Why?
Tissue Distribution
1
1991
46
0.040
Why?
Liver
1
1993
199
0.030
Why?
Refractory Period, Electrophysiological
2
1987
6
0.030
Why?
Intestinal Mucosa
1
1993
212
0.030
Why?
Kinetics
3
1985
279
0.030
Why?
Drug Evaluation, Preclinical
1
1987
34
0.030
Why?
Drug Resistance
1
1987
63
0.030
Why?
Fluorobenzenes
1
1986
3
0.020
Why?
Propanolamines
1
1986
11
0.020
Why?
Wolff-Parkinson-White Syndrome
1
1986
2
0.020
Why?
Tachycardia, Paroxysmal
1
1986
3
0.020
Why?
Calcium Channel Blockers
1
1986
37
0.020
Why?
Heart Atria
2
1985
76
0.020
Why?
Central Nervous System Diseases
1
1985
16
0.020
Why?
Metabolic Diseases
1
1985
14
0.020
Why?
Protriptyline
1
1984
1
0.020
Why?
Syncope
1
1984
7
0.020
Why?
Rubidium
1
1983
6
0.020
Why?
Biological Transport, Active
1
1983
20
0.020
Why?
Cats
3
1979
80
0.020
Why?
Promethazine
1
1980
1
0.020
Why?
Cimetidine
1
1980
2
0.020
Why?
Histamine
1
1980
10
0.020
Why?
Histamine H1 Antagonists
1
1980
9
0.020
Why?
Sorbitol
1
1978
5
0.010
Why?
Isosorbide
1
1978
2
0.010
Why?
Microsatellite Repeats
1
1997
18
0.010
Why?
Pedigree
1
1997
71
0.010
Why?
Gene Frequency
1
1997
82
0.010
Why?
Heterozygote
1
1997
85
0.010
Why?
Autonomic Nervous System
1
1976
25
0.010
Why?
Random Allocation
2
1986
141
0.010
Why?
Digitoxin
1
1974
1
0.010
Why?
Catecholamines
1
1993
16
0.010
Why?
Mathematics
1
1985
34
0.010
Why?
Models, Biological
1
1985
418
0.000
Why?
Mouth Floor
1
1978
2
0.000
Why?
Guinea Pigs
1
1976
69
0.000
Why?
Tritium
1
1974
17
0.000
Why?
Somberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description